Mesenchymal stem cells in treatment of spinal cord injury and amyotrophic lateral sclerosis

0561031 - FZÚ 2023 RIV CH eng J - Článek v odborném periodiku
Syková, E. - Čížková, D. - Kubinová, Šárka
Mesenchymal stem cells in treatment of spinal cord injury and amyotrophic lateral sclerosis.
Frontiers in Cell and Developmental Biology. Roč. 9, July (2021), č. článku 695900. ISSN 2296-634X. E-ISSN 2296-634X
Grant CEP: GA MŠMT(CZ) EF16_019/0000760
Grant ostatní: OP VVV - SOLID21(XE) CZ.02.1.01/0.0/0.0/16_019/0000760
Institucionální podpora: RVO:68378271
Klíčová slova: mesenchymal stem cells * cell therapy * spinal cord injury * amyotrophic lateral sclerosis * neurodegenerative diseases * conditioned medium * exosomes * biomaterials
Obor OECD: Biophysics
Impakt faktor: 6.081, rok: 2021
Způsob publikování: Open access

Preclinical and clinical studies with various stem cells, their secretomes, and extracellular vesicles (EVs) indicate their use as a promising strategy for the treatment of various diseases and tissue defects, including neurodegenerative diseases such as spinal cord injury (SCI) and amyotrophic lateral sclerosis (ALS). Autologous and allogenic mesenchymal stem cells (MSCs) are so far the best candidates for use in regenerative medicine. Here we review the effects of the implantation of MSCs (progenitors of mesodermal origin) in animal models of SCI and ALS and in clinical studies. MSCs possess multilineage differentiation potential and are easily expandable in vitro. These cells, obtained from bone marrow (BM), adipose tissue, Wharton jelly, or even other tissues, have immunomodulatory and paracrine potential, releasing a number of cytokines and factors which inhibit the proliferation of T cells, B cells, and natural killer cells and modify dendritic cell activity.

Trvalý link: https://hdl.handle.net/11104/0333788